These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 30554600)

  • 1. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
    Peppers J; Paller AS; Maeda-Chubachi T; Wu S; Robbins K; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Jan; 80(1):89-98.e3. PubMed ID: 30554600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
    Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
    Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
    J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
    Silverberg JI; Eichenfield LF; Hebert AA; Simpson EL; Stein Gold L; Bissonnette R; Papp KA; Browning J; Kwong P; Korman NJ; Brown PM; Rubenstein DS; Piscitelli SC; Somerville MC; Tallman AM; Kircik L
    J Am Acad Dermatol; 2024 Sep; 91(3):457-465. PubMed ID: 38777187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
    Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
    N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
    Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
    J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
    Lee YW; Won CH; Jung K; Nam HJ; Choi G; Park YH; Park M; Kim B
    Br J Dermatol; 2019 May; 180(5):1030-1038. PubMed ID: 30623408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials.
    Igarashi A; Tsuji G; Fukasawa S; Murata R; Yamane S
    J Dermatol; 2024 Oct; 51(10):1269-1278. PubMed ID: 39150292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials.
    Igarashi A; Tsuji G; Fukasawa S; Murata R; Yamane S
    J Dermatol; 2024 Nov; 51(11):1404-1413. PubMed ID: 39269202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VTAMA
    Gupta AK; Ravi SP; Vincent K; Abramovits W
    Skinmed; 2022; 20(4):298-300. PubMed ID: 35976021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
    Eichenfield LF; Simpson EL; Papp K; Szepietowski JC; Blauvelt A; Kircik L; Silverberg JI; Siegfried EC; Kuligowski ME; Venturanza ME; Kallender H; Ren H; Paller AS
    Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
    Jett JE; McLaughlin M; Lee MS; Parish LC; DuBois J; Raoof TJ; Tabolt G; Wilson T; Somerville MC; DellaMaestra W; Piscitelli SC
    Am J Clin Dermatol; 2022 Jan; 23(1):83-91. PubMed ID: 34713415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
    Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
    J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
    Kim BS; Howell MD; Sun K; Papp K; Nasir A; Kuligowski ME;
    J Allergy Clin Immunol; 2020 Feb; 145(2):572-582. PubMed ID: 31629805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
    Kim BS; Sun K; Papp K; Venturanza M; Nasir A; Kuligowski ME
    J Am Acad Dermatol; 2020 Jun; 82(6):1305-1313. PubMed ID: 32057960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial.
    Bissonnette R; Poulin Y; Zhou Y; Tan J; Hong HC; Webster J; Ip W; Tang L; Lyle M
    Br J Dermatol; 2012 Apr; 166(4):853-60. PubMed ID: 22182053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History.
    Blauvelt A; Kallender H; Sturm D; Li Q; Ren H; Eichenfield LF
    Dermatol Ther (Heidelb); 2024 Nov; 14(11):3161-3174. PubMed ID: 39375281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy.
    Simpson EL; Kircik L; Blauvelt A; Kallender H; Kuo Y; Ren H; Sturm D; Eichenfield LF
    J Dermatol; 2023 Dec; 50(12):1523-1530. PubMed ID: 37830436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
    J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.